{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:11:57Z","timestamp":1782515517447,"version":"3.54.5"},"reference-count":45,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,2,3]],"date-time":"2008-02-03T00:00:00Z","timestamp":1201996800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> Uterine leiomyomas are clinically significant tumours that may develop due to an altered differentiation pathway. We have previously identified a dysregulated retinoic acid (RA) pathway that reduced retinoic exposure in human leiomyoma surgical specimens, and have shown that the leiomyoma phenotype was characterized by excessive and disorganized extracellular matrix (ECM).<\/jats:p><jats:p><jats:bold>Objective\u2002<\/jats:bold> The goal of this study was to determine the impact of RA exposure on the disrupted ECM phenotype of leiomyomas.<\/jats:p><jats:p><jats:bold>Design and methods\u2002<\/jats:bold> Study of immortalized and molecularly confirmed cells generated from surgical specimens of spontaneous uterine leiomyoma and matched myometrium.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> Immortalized leiomyoma and myometrial cells retained the molecular characteristics of their progenitor tissue. Proliferation of leiomyoma cells was inhibited by all<jats:italic>\u2010trans<\/jats:italic> retinoic acid (ATRA). Furthermore, there was a dose\u2010dependent decrease in soluble extracellular collagen protein in ATRA\u2010treated leiomyoma cells. Exposure of leiomyoma cells to ATRA resulted in a dose\u2010dependent inhibition of templates for specific ECM protein production including collagen 1, collagen 4, fibronectin and versican. Notably, expression levels in treated leiomyoma cells approached those found in myometrial cells. These mRNA alterations translated into altered protein. Down\u2010regulation was also observed among the RA pathway genes such as CYP26A1 with exposure to ATRA. Finally, ATRA down\u2010regulated TGF\u2010\u03b23 mRNA expression and the TGF\u2010\u03b2 regulated genes in leiomyoma cells.<\/jats:p><jats:p><jats:bold>Conclusion\u2002<\/jats:bold> Exposure of leiomyomas to ATRA down\u2010regulated cell proliferation, ECM formation, RA metabolism and TGF\u2010\u03b2 regulation, suggesting that RA exposure can alter the leiomyoma phenotype to one that more closely approximates normal myometrium.<\/jats:p>","DOI":"10.1111\/j.1365-2265.2008.03207.x","type":"journal-article","created":{"date-parts":[[2008,2,4]],"date-time":"2008-02-04T05:21:26Z","timestamp":1202102486000},"page":"462-470","source":"Crossref","is-referenced-by-count":78,"title":["Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells"],"prefix":"10.1111","volume":"69","author":[{"given":"Minnie","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Catherino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,8,13]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh017"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.5787"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.12.059"},{"key":"e_1_2_6_5_2","first-page":"197","article-title":"Retinoids as modulators of tumor cells invasion and metastasis","volume":"2","author":"Lotan R.","year":"1991","journal-title":"Seminars in Cancer Biology"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/15419060490471757"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2006.11.093"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.20035"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2006.08.111"},{"key":"e_1_2_6_10_2","first-page":"69","article-title":"Generation of immortal human prostate cell lines for the study of prostate cancer","volume":"81","author":"Rhim J.S.","year":"2003","journal-title":"Methods in Molecular Medicine"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2006.11.098"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/29.9.e45"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00463.2006"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10099"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500174737"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.005769"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.04.030"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(02)00375-7"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-4439(98)00005-2"},{"key":"e_1_2_6_20_2","first-page":"327","volume-title":"Proteoglycans \u2013 Structure, Biology and Molecular Interactions","author":"Zimmermann D.","year":"2000"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208725"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(00)00344-2"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20128"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.913"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(02)03191-6"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.135.1.439"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(02)03154-0"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.118"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2004-1377"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(00)00418-0"},{"key":"e_1_2_6_31_2","first-page":"5737","article-title":"Human uterine leiomyomata express higher levels of peroxisome proliferator\u2010activated receptor gamma, retinoid X receptor \u03b1, and all\u2010trans retinoic acid than myometrium","volume":"59","author":"Tsibris J.C.","year":"1999","journal-title":"Cancer Research"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2002.01641.x"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsgi.2003.09.004"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000077177"},{"key":"e_1_2_6_35_2","first-page":"677","article-title":"Efficacy of LGD1069 (Targretin), a retinoid X receptor\u2010selective ligand, for treatment of uterine leiomyoma","volume":"295","author":"Gamage S.D.","year":"2000","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0272"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2003.09.048"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-215-44113"},{"key":"e_1_2_6_39_2","first-page":"1102","article-title":"Suppression of growth by all\u2010trans retinoic acid requires prolonged induction of interferon regultory factor 1 in cervical squamous carcinoma (SiHa) cells","volume":"9","author":"Arany I.","year":"2002","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200606-862OC"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0008-6363(00)00312-6"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.19.3.1973"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M007431200"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00282.2005"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1811"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.12.100"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2008.03207.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2008.03207.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T20:11:51Z","timestamp":1697227911000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2008.03207.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,13]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1365-2265.2008.03207.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03207.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,13]]}}}